News
1d
MyChesCo on MSNMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Viking Therapeutics has a promising pipeline candidate in the fast-growing therapeutic area of weight loss. Madrigal ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
6don MSN
We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...
We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this ...
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
Explore more
1d
Stocktwits on MSNMadrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On StockShort interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased ...
Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against Nicholas J. Pritzker’s other ...
In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against Billionaire John Paulson’s other stocks with huge upside potential. John Alfred ...
Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.
Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results